A carregar...
Gefitinib (‘Iressa’, ZD1839) and new epidermal growth factor receptor inhibitors
The epidermal growth factor receptor (EGFR) is a promising target for cancer therapy and a number of EGFR-targeted agents have been developed. Those most advanced in development are the EGFR tyrosine kinase inhibitors gefitinib (‘Iressa’, ZD1839) and erlotinib (‘Tarceva’, OSI-774), and the monoclona...
Na minha lista:
| Main Authors: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Nature Publishing Group
2004
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2409596/ https://ncbi.nlm.nih.gov/pubmed/14760365 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6601550 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|